CLY-124 Sickle Cell

Learn More

News, Press, & Publications

News, Press, Publications, & Presentations

Sort by year

Reset
Article Types
Reset

Cellarity Presents on Cell State-Correcting Pipeline Programs for Sickle Cell Disease and Myelofibrosis at 2025 American Society of Hematology Annual Meeting

12.08.25

Press

Read Article

ASH 2025: CLY-124, a first-in-class DCN1 inhibitor partially suppresses CUL3 neddylation and induces fetal hemoglobin is a new potential treatment for sickle cell disease

12.08.25

Presentation

Read Article
/wp-content/uploads/ASH-2025-CLY124-presentation-FINAL.pdf

ASH 2025: Identification of small molecules that selectively target JAK2V617F driven cytokine-independent megakaryopoiesis by leveraging single cell RNA sequencing maps of myelofibrosis patient samples and a deep learning framework

12.06.25

Presentation

Read Article

Cellarity Publishes Groundbreaking Framework for Predicting Drug Safety in Nature Communications

11.13.25

Press

Read Article

A large-scale human toxicogenomics resource for drug-induced liver injury prediction. Nature Communications, 2025.

11.13.25

Publication

Read Article

Cellarity Announces Two Oral Presentations During the 67th American Society of Hematology Annual Meeting

10.31.25

Press

Read Article

Cellarity Publishes Framework for Discovery of Cell State-Correcting Medicines in Science

10.23.25

Press

Read Article

Active learning framework leveraging transcriptomics identifies modulators of disease phenotypes. Science, 2025

10.23.25

Publication

Read Article
https://www.science.org/stoken/author-tokens/ST-3021/full

Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease

06.25.25

Press

Read Article

Ted Myles Joins Cellarity as Chief Executive Officer

05.12.25

Press

Read Article
Load More